Summary of Dupuytren's Disease: Pathology and Management
Dupuytren's Disease: Pathology and Management Explained
Introduction
Dupuytren's disease non-surgical treatments focus on reducing cord tension, rupturing or softening cords, and managing symptomatic nodules and knuckle pads without formal fasciectomy. This material summarizes the main non-surgical approaches that have robust evidence or routine clinical use: enzymatic (collagenase) injection, needle fasciotomy techniques, steroid injections for nodules, and observational/ supportive care. Practical details, safety concerns, and follow-up recommendations are included.
Definition: Non-surgical treatments are interventions that avoid open surgical excision of diseased fascia and instead use injections, percutaneous techniques, or conservative measures to reduce contracture or symptoms.
Main non-surgical options
1) Enzymatic fasciotomy (Collagenase injection)
- What it is: Injection of clostridial collagenase (derived from Clostridium histolyticum) directly into the palpable cord to enzymatically cleave collagen bonds, weakening the cord so it can be ruptured by manipulation.
- Typical dose and technique:
- Standard dose: 0.58 mg of collagenase reconstituted in a small volume (commonly 0.25 mL for cords causing MP contracture; 0.20 mL for cords causing PIP contracture).
- Divide the 0.58-mg dose into thirds and place one third in three closely spaced spots within the cord. The needle should be inserted so the drug goes into the cord, not through it.
- Use a 27-gauge needle and insulin syringe, sterile technique, place cord under tension to identify landmarks before injection.
- Manipulation: Patient returns the next day for passive extension of the affected joint. Protect flexor tendons by flexing the wrist and keep uninvolved joints positioned appropriately (if manipulating MP, keep PIP flexed; if manipulating PIP, keep MP flexed). No general anesthesia usually required.
- Aftercare:
- Bulky dressing initially, patient removes at bedtime and begins stretching exercises.
- Night extension splinting for approximately 3 months.
- Additional injections: in trials, up to 3 injections per joint were permitted at roughly 30-day intervals if contracture not corrected to within 0–5 degrees.
- Efficacy evidence:
- Large phase 3 trials (CORD I, CORD II) found significantly higher rates of correction to 0–5° compared with placebo (e.g., CORD I: 64% vs 6.8%; CORD II: 44.4% vs 4.8%).
- Overall global experience: >2600 injections in >1000 patients at the time of the referenced studies with encouraging outcomes.
- Common adverse events:
- Local: pain, swelling, bruising (ecchymosis), pruritus, lymphadenopathy, transient paresthesia or hypoesthesia.
- Serious but rare: tendon rupture (noted particularly at the little-finger PIP joint during early experience), pulley ligament injury, complex regional pain syndrome, deep venous thrombosis, tendinitis.
- Safety notes and technical modifications to reduce risk:
- Avoid injecting immediately adjacent to the little finger PIP flexion crease; insert needle shallowly (1–3 mm into skin) near that area.
- For fifth-finger central cords, approach the cord in a horizontal plane when possible and keep injection within the cord substance.
- Check tendon function immediately after manipulation: ask patient to flex and extend the finger.
Definition: Enzymatic fasciotomy is the percutaneous injection of an enzyme that digests collagen within Dupuytren’s cords to allow subsequent manual rupture and correction.
2) Percutaneous needle fasciotomy (PNF) and related techniques
- What it is: Mechanical division of the Dupuytren cord by percutaneously passing a needle and repeatedly sawing to weaken or transect the cord, then extending the joint to rupture it.
- When used: Often used for less severe, well-defined cords; historically considered unsuitable for severe contractures affecting multiple structures.
- Advantages: Minimally invasive, quick, often performed under local anesthetic, shorter recovery than open surgery.
Sign up for the full summaryAlready have an account? Sign in
Dupuytren Non-surgical Options
Klíčová slova: Dupuytren's disease overview, Dupuytren's disease anatomy & pathology, Dupuytren's disease treatments & surgery, Dupuytren's disease non-surgical treatments
Klíčové pojmy: Collagenase (0.58 mg) is injected into the cord divided into three aliquots placed within the cord, Manipulation occurs the next day with wrist flexion to protect flexor tendons and night splinting for ~3 months, CORD phase 3 trials showed collagenase corrected 0–5° in 44–64% vs ~5% for placebo, Inject into the cord, not through it; avoid deep insertion near fifth-finger PIP crease, Tendon rupture risk concentrated at little-finger PIP joint; use horizontal approach and shallow depth there, Percutaneous needle fasciotomy is quick and minimally invasive but has higher recurrence and risk of nerve/tendon injury, Triamcinolone injections can regress painful nodules but have ~50% recurrence and unclear long-term effect, Observation is appropriate for asymptomatic nodules; intervene when function is limited (e.g., MP ≥30° or progressing PIP ≥20°), After enzymatic treatment, allow up to 3 injections at ~30-day intervals if needed, Check tendon function immediately after cord rupture by asking patient to flex and extend the finger, Common local adverse events after collagenase: pain, swelling, bruising, lymphadenopathy; most resolve in weeks, Recurrence at 5 years after enzymatic treatment approximately 10% for MP joints and 20% for PIP joints